Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$49.05

-0.26 (-0.53%)

, MRK

Merck

$88.75

-0.54 (-0.60%)

13:33
12/17/19
12/17
13:33
12/17/19
13:33

AstraZeneca says FDA advisors recommend Lynparza for gBRCAm pancreatic cancer

AstraZeneca (AZN) and Merck (MRK) announced that the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee voted 7 to 5 to recommend Lynparza as a 1st-line maintenance monotherapy for patients with germline BRCA-mutated, or gBRCAm, metastatic adenocarcinoma of the pancreas whose disease has not progressed following 1st-line platinum-based chemotherapy. In August, the FDA accepted the supplemental New Drug Application for Lynparza for this indication with Priority Review and set a Prescription Drug User Fee Act date for the fourth quarter of 2019. Jose Baselga, Executive Vice President, Oncology R&D, said: "We are pleased with the ODAC's recommendation for Lynparza and the potential to bring a personalised, biomarker-targeted medicine to patients with germline BRCA-mutated metastatic pancreatic cancer. Patients with advanced pancreatic cancer historically have faced poor outcomes due to the aggressive nature of the disease and limited treatment advances over the last few decades. We look forward to working with the FDA as it completes the review of our application."

AZN

AstraZeneca

$49.05

-0.26 (-0.53%)

MRK

Merck

$88.75

-0.54 (-0.60%)

  • 17

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

AZN AstraZeneca
$49.05

-0.26 (-0.53%)

12/02/19
COWN
12/02/19
NO CHANGE
Target $55
COWN
Outperform
AstraZeneca price target raised to $55 from $48 at Cowen
Cowen analyst Steve Scala raised his price target on AstraZeneca to $55 from $48 as he believes its product momentum and high relative growth are not recognized. The analyst believes there is opportunity for upside as forecasts are below the company's guidance and its low relative exposure to the U.S. makes it less vulnerable to election rhetoric. Scala reiterated his Outperform rating on AstraZeneca shares.
12/12/19
DBAB
12/12/19
DOWNGRADE
Target $1570
DBAB
Hold
Genmab downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Richard Parkes downgraded Genmab (GMAB) to Hold from Buy with a DKK 1,570 price target. The analyst says the current valuation reflects the company's pipeline. AstraZeneca (AZN) and Roche (RHHBY) are his top large cap picks in European pharmaceuticals due to their "innovation advantage."
12/12/19
HCWC
12/12/19
NO CHANGE
HCWC
Zymeworks may have work-around to AEs of competing drug, says H.C. Wainwright
After AstraZeneca (AZN) and Daiichi Sankyo reported updated clinical data from DS-8201a at the SABCS meeting, H.C. Wainwright analyst Debjit Chattopadhyay said the 14% interstitial lung disease rates are "potentially problematic to physicians" and could limit positioning in earlier lines of therapy despite the drug being "compelling." However, this potential disadvantage is unlikely to be mirrored by Zymeworks' (ZYME) ZW25 and ZW49 for multiple HER2+ breast cancers, contends Chattopadhyay. The analyst keeps a Buy rating on Zymeworks shares.
12/16/19
STFL
12/16/19
DOWNGRADE
Target $28
STFL
Hold
Stifel 'taking profits' on Amarin following FDA approval, downgrades to Hold
Stifel analyst Derek Archila downgraded Amarin (AMRN) to Hold from Buy with a price target of $28, up from $26, after the FDA approved Vascepa for an expanded indication as an adjunct therapy in patients on statins with high triglycerides who have established CV disease and also for diabetic patients with greater than 2 cardiovascular risk factors. While he said "there is no doubt in our mind Vascepa will be a multi-billion dollar product," Archila prefers to "take profits" at the stock's current valuation near $11B fully diluted. He also points to unpredictability around Vascepa's intellectual property litigation, the drug's "relatively short" exclusivity period, and AstraZeneca's (AZN) Epanova CVOT results next year as downside risks.
MRK Merck
$88.75

-0.54 (-0.60%)

12/10/19
HCWC
12/10/19
DOWNGRADE
Target $20
HCWC
Neutral
ArQule downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Edward White downgraded ArQule (ARQL) to Neutral from Buy with a price target of $20, up from $13. The analyst cites the proposed takeover by Merck (MRK) for the downgrade.
12/10/19
CANT
12/10/19
DOWNGRADE
Target $20
CANT
Neutral
ArQule downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Varun Kumar downgraded ArQule (ARQL) to Neutral from Overweight with a price target of $20, up from $16. Although other bidders may emerge, the proposed acquisition value paid by Merck (MRK) is fair and makes a "great strategic fit for both parties," Kumar tells investors in a research note.
12/10/19
ROTH
12/10/19
DOWNGRADE
Target $18
ROTH
Neutral
ArQule downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Tony Butler downgraded ArQule (ARQL) to Neutral from Buy with a price target of $18, down from $20, after the company agreed to be acquired by Merck (MRK) for $20 per share in cash for a total equity value of approximately $2.7B. Butler tells investors in a research note that he believes with ArQule's non-covalent BTK inhibitor ARQ 531, Merck may be able to strategically diversify its product portfolio and have an increasing presence in hematologic malignancies.
12/12/19
STFL
12/12/19
NO CHANGE
Target $17
STFL
Buy
Stifel says TherapeuticsMD's Annovera 'insulated' against generic NuvaRing
After Amneal Pharmaceuticals (AMRX) announced this morning that it has received approval from the FDA to market EluRyng, the first generic version of Merck's (MRK) NuvaRing Stifel analyst Annabel Samimy said the new contraceptive vaginal ring entrant may pose a threat to NuvaRing, but she believes TherapeuticsMD's (TXMD) competitor in the class, Annovera, is "insulated" by key product profile distinctions. Samimy points to Annovera's differentiated progesterone and long-acting system to support her view that Annovera successful early launch should shielded from disruption. She maintains a Buy rating and $17 price target on TherapeuticsMD shares.

TODAY'S FREE FLY STORIES

ERIC

Ericsson

$8.89

-0.115 (-1.28%)

12:55
01/21/20
01/21
12:55
01/21/20
12:55
Periodicals
Trump says working with Ericsson, opening up spectrum, Bloomberg reports »

Bloomberg cites comments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

12:55
01/21/20
01/21
12:55
01/21/20
12:55
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

GOOGL

Alphabet Class A

$1,483.50

4.38 (0.30%)

, GOOG

Alphabet

$1,484.43

4.15 (0.28%)

12:55
01/21/20
01/21
12:55
01/21/20
12:55
Periodicals
Sonos, others testify on big tech anti-competition before Congress, Verge says »

In an antitrust hearing…

GOOGL

Alphabet Class A

$1,483.50

4.38 (0.30%)

GOOG

Alphabet

$1,484.43

4.15 (0.28%)

SONO

Sonos

$15.01

-0.11 (-0.73%)

FB

Facebook

$221.57

-0.44 (-0.20%)

AMZN

Amazon.com

$1,870.50

6.1 (0.33%)

AAPL

Apple

$318.28

-0.38 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 27

    Jan

  • 28

    Jan

  • 29

    Jan

  • 30

    Jan

  • 03

    Feb

  • 03

    Feb

  • 05

    Feb

  • 10

    Feb

12:55
01/21/20
01/21
12:55
01/21/20
12:55
Conference/Events
Senate Impeachment Trial of President Trump »

The Senate Impeachment…

MSFT

Microsoft

$167.73

0.67 (0.40%)

, GOOGL

Alphabet Class A

$1,483.50

4.38 (0.30%)

12:53
01/21/20
01/21
12:53
01/21/20
12:53
On The Fly
Fly Intel: What to watch in IBM's earnings report »

IBM (IBM) is scheduled to…

MSFT

Microsoft

$167.73

0.67 (0.40%)

GOOGL

Alphabet Class A

$1,483.50

4.38 (0.30%)

HPE

HP Enterprise

$14.96

-0.14 (-0.93%)

GOOG

Alphabet

$1,484.43

4.15 (0.28%)

NTAP

NetApp

$61.27

-1.14 (-1.83%)

IBM

IBM

$139.00

0.69 (0.50%)

PSTG

Pure Storage

$18.46

-0.03 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 29

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

  • 25

    Feb

  • 10

    Mar

  • 11

    Mar

EAF

GrafTech

$12.06

0.05 (0.42%)

12:45
01/21/20
01/21
12:45
01/21/20
12:45
Options
GrafTech call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

AMGN

Amgen

$239.06

-2.47 (-1.02%)

, CYTK

Cytokinetics

$12.19

0.02 (0.16%)

12:36
01/21/20
01/21
12:36
01/21/20
12:36
Recommendations
Amgen, Cytokinetics analyst commentary  »

Piper says Cytokinetics…

AMGN

Amgen

$239.06

-2.47 (-1.02%)

CYTK

Cytokinetics

$12.19

0.02 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 30

    Jan

VFC

VF Corp.

$94.63

0.38 (0.40%)

12:35
01/21/20
01/21
12:35
01/21/20
12:35
Recommendations
VF Corp. analyst commentary  »

Stifel sees benefits in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

UBSFY

Ubisoft

$0.00

(0.00%)

, TCEHY

Tencent

$0.00

(0.00%)

12:29
01/21/20
01/21
12:29
01/21/20
12:29
On The Fly
Game On: An exclusive talk with Cloudhead Games CEO Denny Unger »

This week's edition of…

UBSFY

Ubisoft

$0.00

(0.00%)

TCEHY

Tencent

$0.00

(0.00%)

TTWO

Take-Two

$130.68

0.7 (0.54%)

EA

Electronic Arts

$112.86

-0.06 (-0.05%)

ATVI

Activision Blizzard

$61.58

0.35 (0.57%)

NTDOY

Nintendo

$0.00

(0.00%)

MSFT

Microsoft

$167.55

0.49 (0.29%)

FB

Facebook

$221.28

-0.73 (-0.33%)

SNE

Sony

$72.38

-0.1 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

  • 29

    Jan

  • 30

    Jan

  • 03

    Feb

  • 04

    Feb

  • 06

    Feb

  • 06

    Feb

  • 13

    Feb

  • 13

    Feb

  • 14

    Feb

  • 18

    Feb

  • 25

    Feb

MSM

MSC Industrial

$71.05

4.91 (7.42%)

12:28
01/21/20
01/21
12:28
01/21/20
12:28
Conference/Events
MSC Industrial management to meet with KeyBanc »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 29

    Jan

SDC

SmileDirectClub

$13.00

0.105 (0.81%)

12:25
01/21/20
01/21
12:25
01/21/20
12:25
Options
SmileDirectClub call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
01/21/20
01/21
12:17
01/21/20
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
01/21/20
01/21
12:16
01/21/20
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$88.47

-0.21 (-0.24%)

12:13
01/21/20
01/21
12:13
01/21/20
12:13
Periodicals
Philip Morris CEO wants tobacco advertising rules relaxed, Telegraph says »

Philip Morris…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$24.37

0.41 (1.71%)

, VFC

VF Corp.

$94.68

0.43 (0.46%)

12:10
01/21/20
01/21
12:10
01/21/20
12:10
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks in the U.S. opened…

HAL

Halliburton

$24.37

0.41 (1.71%)

VFC

VF Corp.

$94.68

0.43 (0.46%)

COLM

Columbia Sportswear

$98.09

2.5 (2.62%)

YETI

Yeti

$35.95

1.72 (5.02%)

AAL

American Airlines

$27.85

-0.54 (-1.90%)

DAL

Delta Air Lines

$59.78

-2.23 (-3.60%)

UAL

United Airlines

$86.72

-2.96 (-3.30%)

LVS

Las Vegas Sands

$71.07

-3 (-4.05%)

WYNN

Wynn Resorts

$144.98

-6.53 (-4.31%)

MLCO

Melco Resorts & Entertainment

$23.31

-1.7 (-6.80%)

OMI

Owens & Minor

$6.49

0.97 (17.57%)

BYND

Beyond Meat

$123.42

14.22 (13.02%)

SBUX

Starbucks

$93.09

-0.53 (-0.57%)

ARWR

Arrowhead

$49.05

-7.37 (-13.06%)

WW

WW

$38.50

-3.43 (-8.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 23

    Jan

  • 23

    Jan

  • 28

    Jan

  • 06

    Feb

  • 04

    Mar

  • 23

    Mar

SCWX

Secureworks

$16.55

0.19 (1.16%)

12:07
01/21/20
01/21
12:07
01/21/20
12:07
Hot Stocks
Secureworks, Carahsoft expand partnership »

Carahsoft Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$11.15

1.18 (11.84%)

12:05
01/21/20
01/21
12:05
01/21/20
12:05
Options
Cel Sci call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

MDT

Medtronic

$120.36

1.38 (1.16%)

12:03
01/21/20
01/21
12:03
01/21/20
12:03
Hot Stocks
Medtronic announces FDA approval of Medtronic Micra AV »

Medtronic announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 18

    Feb

CCL

Carnival

$51.01

-0.89 (-1.71%)

, NCLH

Norwegian Cruise Line

$58.83

-0.83 (-1.39%)

12:02
01/21/20
01/21
12:02
01/21/20
12:02
Recommendations
Carnival, Norwegian Cruise Line, Royal Caribbean analyst commentary  »

Coronavirus outbreak…

CCL

Carnival

$51.01

-0.89 (-1.71%)

NCLH

Norwegian Cruise Line

$58.83

-0.83 (-1.39%)

RCL

Royal Caribbean

$129.95

-5.09 (-3.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

OMI

Owens & Minor

$6.40

0.88 (15.94%)

12:00
01/21/20
01/21
12:00
01/21/20
12:00
Hot Stocks
Owens & Minor rises 16.2% »

Owens & Minor is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNK

Mallinckrodt

$6.14

0.935 (17.96%)

12:00
01/21/20
01/21
12:00
01/21/20
12:00
Hot Stocks
Mallinckrodt rises 18.2% »

Mallinckrodt is up 18.2%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Mar

CSS

CSS Industries

$9.35

4.65 (98.94%)

12:00
01/21/20
01/21
12:00
01/21/20
12:00
Hot Stocks
CSS Industries rises 99.4% »

CSS Industries is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$21.49

1.58 (7.94%)

, RDY

Dr. Reddy's

$42.64

0.2 (0.47%)

11:59
01/21/20
01/21
11:59
01/21/20
11:59
On The Fly
Amarin seen in 'good position' as Vascepa patent trial proceeds »

Following the fourth day…

AMRN

Amarin

$21.49

1.58 (7.94%)

RDY

Dr. Reddy's

$42.64

0.2 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jan

11:57
01/21/20
01/21
11:57
01/21/20
11:57
Conference/Events
Morgan Stanley energy analysts to hold an analyst/industry conference call »

Analysts, along with Stu…

TPR

Tapestry

$28.46

-0.43 (-1.49%)

11:55
01/21/20
01/21
11:55
01/21/20
11:55
Options
Tapestry put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.